Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals focuses on developing therapies for rare chronic neuromuscular and neurological diseases. They offer Firdapse for Lambert-Eaton Myasthenic Syndrome (LEMS) patients. Ruzurgi treats pediatric LEMS patients. Firdapse also targets MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. The company has license agreements with BioMarin Pharmaceutical Inc. and Endo Ventures Limited. It was founded in 2002 and is based in Coral Gables, Florida.
Overview
Strengths
- With an appreciation Potential of 148.47%, based on our fundamental analysis, it suggests the stock may be undervalued.
- Current Price to Earnings Ratio (17.35) is lower than the sector mean (91.15).
- The company has low debt. Net Debt to EBITDA Ratio is -2.26 and it is lower than the sector mean.
- The company has high returns. ROIC (32.81%) is higher than the sector mean (6.02%).
- EV/EBITDA (10.23) is lower than the sector mean (85.60).
- EV/EBIT (11.94) is lower than the sector mean.
- Price to free cash flow (11.89) is lower than the sector mean.
- Strong EBITDA Margin of 46.33%.
Weaknesses
- No significant weaknesses identified based on the analyzed metrics.
Key Financial Data
| Indicator | Value |
|---|
| PER | 17.4 |
| EV/EBITDA | 10.2 |
| Price/Free Cash Flow' | 11.9 |
| ROIC | 32.8% |
| Net Debt/EBITDA | -2.3 |